Chiltern Announces Strong Growth in FSP Relationships in Western Europe
pharmafile | December 7, 2009 | News story | Research and Development |
All CRAs will be seconded via Chiltern’s European Resourcing Solutions team and fully allocated to the company under a Functional Service or FSP model. The Chiltern CRAs will work directly with the client Project Managers to ensure high quality and timely delivery.
Another leading pharmaceutical company also selected Chiltern as the sole provider of an FSP relationship within their pharmacovigilance team. Chiltern’s in house expertise in the area coupled with access to Chiltern training and development with dedicated Chiltern line management for the staff has proven to be an excellent service offering.
FSP relationships are gaining popularity in the industry due to the flexibility in resource allocations and the cost savings they can offer to clients.
“These are great achievements for Chiltern,” commented Linda Christmas, Chiltern Executive Vice President, Resourcing Solutions, “and helps us meet our target to develop strategically aligned relationships with our clients, offering a flexible and cost effective yet high quality solution. We are delighted that we have been able to partner with two more leading pharmaceutical companies in two different core functions, drawing on our expertise both in clinical trials and resourcing.”
Company profile
About Chiltern:
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 29 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information is available at www.chiltern.com.
